CERT Certara

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • UBS Global Healthcare Conference

    Date and Time: Tuesday, November 11th 2025 at 2:00PM ET
  • Jefferies Global Healthcare Conference in London

    Date and Time: Tuesday, November 18th 2025 at 10:30AM GMT
  • Stephens Annual Investment Conference

    Date and Time: Tuesday, November 18th 2025 at 1:00PM CT

Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
31/10/2025

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Third Quarter 2025 Financial Results

Certara Reports Third Quarter 2025 Financial Results  Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 m...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL St...

November 4, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: UBS Global Healthcare ConferenceDate and Time: Tuesday, November 11th 2025 at 2:00PM ET Jefferies Global Healthcare Conference in LondonDate and Time: Tuesday, November 18th 2025 at 10:30AM GMT Stephens Annual Investment ConferenceDate and Time: Tuesday, November 18th 2025 at 1:00PM CT Live webcasts for each ...

October 31, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Certara Expands Biosimulation Market with AI-Driven QSP Platform Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly doubled every 1...

October 30, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Scientists are Among the Topmost Cited Biopharma Researchers

Certara Scientists are Among the Topmost Cited Biopharma Researchers Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the  of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific k...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch